^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    c-MET-targeted antibody-drug conjugate

    Related drugs:
    1d
    A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2/3, N=900, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • telisotuzumab adizutecan (ABBV-400)
    7d
    A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    New P2 trial
    |
    Keytruda (pembrolizumab) • cisplatin • Tagrisso (osimertinib) • carboplatin • Ivesa (firmonertinib)
    13d
    AndroMETa-CRC-064: A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=74, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=460 --> 74 | Trial completion date: Oct 2028 --> Aug 2027 | Trial primary completion date: Oct 2028 --> Aug 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Adverse events
    |
    telisotuzumab adizutecan (ABBV-400)
    19d
    Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. (clinicaltrials.gov)
    P2, N=252, Not yet recruiting, Shanghai Allink Biotherapeutics Co., Ltd.
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR expression • MET expression
    |
    Tagrisso (osimertinib) • carboplatin • Idafang (ivonescimab)
    28d
    A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    29d
    SKB571-II-02: A Phase II Study of SKB571 in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=295, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | N=190 --> 295
    Enrollment change
    1m
    Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | Trial completion date: Sep 2028 --> Dec 2027 | Trial primary completion date: Sep 2028 --> Dec 2027
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Adverse events
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    |
    telisotuzumab adizutecan (ABBV-400)
    1m
    EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov)
    P1, N=403, Recruiting, AstraZeneca | Trial completion date: Oct 2027 --> Aug 2028 | Trial primary completion date: Oct 2027 --> Aug 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR wild-type
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • 5-fluorouracil • leucovorin calcium • tilatamig samrotecan (AZD9592)
    1m
    A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection (clinicaltrials.gov)
    P1/2, N=465, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. (PubMed, J Clin Oncol)
    Temab-A at 2.4 mg/kg once every 3 weeks has a tolerable and manageable safety profile, with promising antitumor activity.
    P1 data • Journal • First-in-human
    |
    BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    BRAF wild-type
    |
    telisotuzumab adizutecan (ABBV-400) • telisotuzumab (h224G11)
    1m
    An evaluation of telisotuzumab vedotin for the treatment of non-squamous non-small cell lung cancer. (PubMed, Expert Opin Biol Ther)
    While accelerated approval underscores its therapeutic promise, long-term positioning will depend on confirmatory trials, refinement of biomarker testing, and optimization of patient selection. If validated, this strategy may redefine later-line treatment expectations by aligning cytotoxic payload delivery with biologically enriched disease subsets.
    Review • Journal • IO Companion diagnostic • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR wild-type • MET overexpression
    |
    Emrelis (telisotuzumab vedotin-tllv)
    2ms
    A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. (PubMed, Cell Rep Med)
    In preclinical studies, B6ADC exhibits potent cytotoxicity in vitro across various TROP2/c-Met-expressing cancer cell lines and superior tumor inhibition in vivo compared with single-target ADC combination, including the clinically approved TROP2 ADC sacituzumab govitecan and c-Met ADC Teliso-V, as well as their combination. Notably, B6ADC eradicates giant tumors with a single dose at a low concentration of 2.2 mg/kg. We present a nanobody-based BsADC that simultaneously targets TROP2 and c-Met, with broad-spectrum antitumor activity, and improves selectivity for tumors with dual-positive or weakly positive antigen expression, offering a promising strategy for treating pancreatic cancer and other TROP2/c-Met-expressing malignancies.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    MET expression
    |
    Trodelvy (sacituzumab govitecan-hziy) • Emrelis (telisotuzumab vedotin-tllv)